Literature DB >> 33091559

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

B Eichhorst1, T Robak2, E Montserrat3, P Ghia4, C U Niemann5, A P Kater6, M Gregor7, F Cymbalista8, C Buske9, P Hillmen10, M Hallek11, U Mey12.   

Abstract

Entities:  

Keywords:  B-cell receptor inhibitors; BCL2 inhibitor; chronic lymphocytic leukaemia; individualised therapy; prognostic factors; targeted treatment

Mesh：

Year:  2020        PMID： 33091559     DOI： 10.1016/j.annonc.2020.09.019

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  48 in total

1.  Frontline treatment in CLL: the case for time-limited treatment.

Authors:  Vincent Lévy; Alain Delmer; Florence Cymbalista
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Lymphocytosis and chronic lymphocytic leukaemia: investigation and management.

Authors:  Amarpreet Devi; Lieze Thielemans; Eleni E Ladikou; Taran K Nandra; Timothy Chevassut
Journal:  Clin Med (Lond)       Date:  2022-05       Impact factor: 5.410

Review 3.  New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.

Authors:  Elżbieta Iskierka-Jażdżewska; Agnieszka Obracaj; Marta Urbaniak; Tadeusz Robak
Journal:  Curr Treat Options Oncol       Date:  2022-03-31

4.  Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).

Authors:  Anthony R Mato; Matthew S Davids; Jeff Sharman; Lindsey E Roeker; Neil Kay; Arnon P Kater; Kerry Rogers; Meghan C Thompson; Joanna Rhodes; Andre Goy; Alan Skarbnik; Stephen J Schuster; Constantine S Tam; Toby A Eyre; Susan O'Brien; Chadi Nabhan; Nicole Lamanna; Clare Sun; Mazyar Shadman; John M Pagel; Chaitra Ujjani; Danielle Brander; Catherine C Coombs; Nitin Jain; Chan Y Cheah; Jennifer R Brown; John F Seymour; Jennifer A Woyach
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

Review 5.  Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2020-12       Impact factor: 9.546

6.  Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Inhye E Ahn; Carsten U Niemann; Christian Brieghel; Kathrine Aarup; Mathias H Torp; Michael A Andersen; Christina W Yde; Xin Tian; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2021-05-07       Impact factor: 13.801

7.  Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients.

Authors:  Mariam Ibáñez; Esperanza Such; Alessandro Liquori; Gayane Avestisyan; Rafael Andreu; Ana Vicente; María José Macián; Mari Carmen Melendez; Mireya Morote-Faubel; Pedro Asensi; María Pilar Lloret; Isidro Jarque; Isabel Picón; Alejandro Pacios; Eva Donato; Carmen Mas-Ochoa; Carmen Alonso; Carolina Cañigral; Amparo Sempere; Samuel Romero; Marta Santiago; Guillermo F Sanz; Javier de la Rubia; Leonor Senent; Irene Luna
Journal:  Diagnostics (Basel)       Date:  2022-04-11

8.  Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

Authors:  John N Allan; Tait Shanafelt; Adrian Wiestner; Carol Moreno; Susan M O'Brien; Jianling Li; Gabriel Krigsfeld; James P Dean; Inhye E Ahn
Journal:  Br J Haematol       Date:  2021-12-05       Impact factor: 8.615

Review 9.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10

Review 10.  Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.

Authors:  Romeo Gabriel Mihaila
Journal:  Oncol Lett       Date:  2021-07-03       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.